Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alverine is a small molecule antispasmodic drug used primarily to relieve abdominal pain and discomfort associated with gastrointestinal conditions such as irritable bowel syndrome (IBS) and diverticular disease, as well as painful menstruation (dysmenorrhea)[1][2][3][5]. It acts directly on smooth muscle in the gut and uterus, causing relaxation and thereby reducing spasms that lead to pain[1][2][3]. Alverine’s mechanism of action includes direct smooth muscle relaxation—possibly through inhibition of L-type calcium channel inactivation—and antagonism at the 5-hydroxytryptamine receptor 1A, which may reduce rectal hypersensitivity[5][6]. The drug is available in capsule form (commonly 60 mg or 120 mg) for adults and children over 12 years old. It is approved for use in several countries for functional gastrointestinal disorders. **Developers:** Dr. Reddy's Laboratories
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alverine.